Printed From BioPortfolio.com
International Stem Cell (ISCO) - Interim Parkinson’s data
08:38 EST 3 Jan 2018 | Edison Investment Research
Edison Investment Research - Pharmaceutical & healthcare - International Stem Cell : International Stem Cell recently announced interim six-month results from the first cohort of four patients in its Phase I trial of ISC-hpNSC in Parkinson’s disease (PD). Positive signals were seen in a variety of measures, which include daily living, mobility, depression and compulsive disorders. The trial is continuing and the second cohort is almost enrolled, with the third patient of four recently undergoing surgical implantation. The study will enroll 12 patients at three dosing regimens (30-70m cells).
ISIN: US4603782016
Original Article: International Stem Cell (ISCO) - Interim Parkinson’s data
